Drug firm Natco Pharma on Wednesday reported a 34.46 per cent drop in consolidated net profit to Rs 104.4 crore for the quarter ended December 2019.
The company had posted a net profit of Rs 159.3 crore for the corresponding period of the previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
"The company continues to face margin pressures in its Hepatitis C portfolio," the filing said.
The company's board has recommended a third interim dividend of Rs 3.50 per equity share of Rs 2 each.
Shares of Natco Pharma closed at Rs 712 per scrip on BSE, down 0.59 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
